Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The worldwide Urological Cancer Drugs market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 14.9% during the forecast period.
This report presents the market size and development trends by detailing the Urological Cancer Drugs market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Urological Cancer Drugs market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Urological Cancer Drugs industry and will help you to build a panoramic view of the industrial development.
Urological Cancer Drugs Market, By Type:
Xofigo (Radium Ra 223 Dichloride)
Jevtana (Cabazitaxel)
Inlyta (Axitinib)
Votrient (Pazopanib Hydrochloride)
Sutent (Sunitinib Malate)
Zytiga (Abiraterone Acetate)
Xtandi (Enzalutamide)
Opdivo (Nivolumab)
Provenge (Sipuleucel-T)
Urological Cancer Drugs Market, By Application:
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular Cancer
Some of the leading players are as follows:
Abbott Laboratories
Novartis
Sanofi SA
Bristol-Myers Squibb
Astellas
Sanofi S.A.
AstraZeneca
Ipsen
Johnson & Johnson
Indevus Pharmaceuticals Inc
Pfizer
Celgene Corporation
GlaxoSmithKline
Ferring Pharmaceuticals
Dendreon Corporation
Roche Healthcare
Geographically, Major regions are analyzed in details are as follows:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East & Africa
Table of Contents
1 Methodology and Scope
-
1.1 Market Segmentation & Scope
-
1.1.1 Technology Type
-
1.1.2 Product
-
1.1.3 Application
-
1.1.4 Regional scope
-
1.1.5 Estimates and forecast timeline
-
1.2 Research Methodology
-
1.3 Information Procurement
-
1.3.1 Purchased database
-
1.3.2 Internal database
-
1.3.3 Secondary sources
-
1.3.4 Primary research
-
1.3.5 Details of primary research
-
1.4 Information or Data Analysis
-
1.4.1 Data analysis models
-
1.5 Market Formulation & Validation
-
1.6 Model Details
-
1.6.1 Commodity flow analysis
-
1.6.2 Volume price analysis
-
1.7 List of Secondary Sources
-
1.8 List of Abbreviations
2 Executive Summary
-
2.1 Market Outlook
-
2.2 Segment Outlook
3 Market Variables, Trends, & Scope
-
3.1 Market Lineage Outlook
-
3.1.1 Parent market outlook
-
3.1.2 Ancillary market outlook
-
3.2 Market Segmentation
-
3.2.1 Analysis
-
3.3 Market Dynamics
-
3.3.1 Market driver analysis
-
3.3.2 Market restraint analysis
-
3.3.3 Industry opportunities
-
3.4 Penetration & Growth Prospect Mapping
-
3.4.1 Penetration & growth prospect mapping analysis
-
3.5 Business Environment Analysis Tools
-
3.5.1 Porter's five forces analysis
-
3.5.2 PESTLE analysis
-
3.5.3 Major deals & strategic alliances analysis
4 Urological Cancer Drugs Market: Technology Type Analysis
-
4.1 Urological Cancer Drugs Technology Type Market Share Analysis, 2018 & 2026
-
4.2 Urological Cancer Drugs Technology Type Market: Segment Dashboard
-
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment
4.3.1 Xofigo (Radium Ra 223 Dichloride)
4.3.2 Jevtana (Cabazitaxel)
4.3.3 Inlyta (Axitinib)
4.3.4 Votrient (Pazopanib Hydrochloride)
4.3.5 Sutent (Sunitinib Malate)
4.3.6 Zytiga (Abiraterone Acetate)
4.3.7 Xtandi (Enzalutamide)
4.3.8 Opdivo (Nivolumab)
4.3.9 Provenge (Sipuleucel-T)
5 Urological Cancer Drugs Market: Product Analysis
-
5.1 Urological Cancer Drugs Product Market Share Analysis, 2018 & 2026
-
5.2 Urological Cancer Drugs Product Market: Segment Dashboard
-
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment
6 Urological Cancer Drugs Market: Application Analysis
-
6.1 Urological Cancer Drugs Application Market Share Analysis, 2018 & 2026
-
6.2 Urological Cancer Drugs Application Market: Segment Dashboard
-
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment
6.3.1 Prostate Cancer
6.3.2 Bladder Cancer
6.3.3 Kidney Cancer
6.3.4 Testicular Cancer
7 Urological Cancer Drugs Market: Regional Analysis
-
7.1 Urological Cancer Drugs Regional Market Share Analysis, 2018 & 2026
-
7.2 Urological Cancer Drugs Regional Market: Segment Dashboard
-
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
-
7.4 List of Players at Regional Level
-
7.4.1 North America
-
7.4.2 Europe
-
7.4.3 Asia Pacific
-
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
-
7.5.1 North America
-
7.5.2 Europe
-
7.5.3 Asia Pacific
-
7.5.4 Latin America
-
7.5.5 MEA
-
7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026
-
7.6.1 North America
-
7.6.2 Europe
-
7.6.3 Asia Pacific
-
7.6.4 Latin America
-
7.6.5 Middle East & Africa
8 Competitive Analysis
-
8.1 Recent Developments & Impact Analysis, by Key Market Participants
-
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
-
8.3 Vendor Landscape
-
8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)
9 Company Profiles
9.1 Abbott Laboratories
9.1.1 Abbott Laboratories Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis
9.2 Novartis
9.2.1 Novartis Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis
9.3 Sanofi SA
9.3.1 Sanofi SA Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis
9.4 Bristol-Myers Squibb
9.4.1 Bristol-Myers Squibb Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 Astellas
9.5.1 Astellas Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis
9.6 Sanofi S.A.
9.6.1 Sanofi S.A. Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.6.5 SWOT analysis
9.7 AstraZeneca
9.7.1 AstraZeneca Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.7.5 SWOT analysis
9.8 Ipsen
9.8.1 Ipsen Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.8.5 SWOT analysis
9.9 Johnson & Johnson
9.9.1 Johnson & Johnson Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.9.5 SWOT analysis
9.10 Indevus Pharmaceuticals Inc
9.10.1 Indevus Pharmaceuticals Inc Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.10.5 SWOT analysis
9.11 Pfizer
9.11.1 Pfizer Company overview
9.11.2 Financial performance
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
9.11.5 SWOT analysis
9.12 Celgene Corporation
9.12.1 Celgene Corporation Company overview
9.12.2 Financial performance
9.12.3 Product benchmarking
9.12.4 Strategic initiatives
9.12.5 SWOT analysis
9.13 GlaxoSmithKline
9.13.1 GlaxoSmithKline Company overview
9.13.2 Financial performance
9.13.3 Product benchmarking
9.13.4 Strategic initiatives
9.13.5 SWOT analysis
9.14 Ferring Pharmaceuticals
9.14.1 Ferring Pharmaceuticals Company overview
9.14.2 Financial performance
9.14.3 Product benchmarking
9.14.4 Strategic initiatives
9.14.5 SWOT analysis
9.15 Dendreon Corporation
9.15.1 Dendreon Corporation Company overview
9.15.2 Financial performance
9.15.3 Product benchmarking
9.15.4 Strategic initiatives
9.15.5 SWOT analysis
9.16 Roche Healthcare
9.16.1 Roche Healthcare Company overview
9.16.2 Financial performance
9.16.3 Product benchmarking
9.16.4 Strategic initiatives
9.16.5 SWOT analysis
The List of Tables and Figures (Totals 104 Figures and 140 Tables)
Figure Xofigo (Radium Ra 223 Dichloride) Urological Cancer Drugs market, 2015 - 2026 (USD Million)
Figure Jevtana (Cabazitaxel) Urological Cancer Drugs market, 2015 - 2026 (USD Million)
Figure Inlyta (Axitinib) Urological Cancer Drugs market, 2015 - 2026 (USD Million)
Figure Votrient (Pazopanib Hydrochloride) Urological Cancer Drugs market, 2015 - 2026 (USD Million)
Figure Sutent (Sunitinib Malate) Urological Cancer Drugs market, 2015 - 2026 (USD Million)
Figure Zytiga (Abiraterone Acetate) Urological Cancer Drugs market, 2015 - 2026 (USD Million)
Figure Xtandi (Enzalutamide) Urological Cancer Drugs market, 2015 - 2026 (USD Million)
Figure Opdivo (Nivolumab) Urological Cancer Drugs market, 2015 - 2026 (USD Million)
Figure Provenge (Sipuleucel-T) Urological Cancer Drugs market, 2015 - 2026 (USD Million)
Figure Prostate Cancer market, 2015 - 2026 (USD Million)
Figure Bladder Cancer market, 2015 - 2026 (USD Million)
Figure Kidney Cancer market, 2015 - 2026 (USD Million)
Figure Testicular Cancer market, 2015 - 2026 (USD Million)
-
Table List of players in North America
-
Table List of players in Europe
-
Table List of players in Asia Pacific
-
Table SWOT analysis
-
Table North America Urological Cancer Drugs market, by country, 2015 - 2026 (USD Million)
-
Table North America Urological Cancer Drugs market, by type, 2015 - 2026 (USD Million)
-
Table North America Urological Cancer Drugs market, by product, 2015 - 2026 (USD Million)
-
Table North America Urological Cancer Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.S. Urological Cancer Drugs market, by type, 2015 - 2026 (USD Million)
-
Table U.S. Urological Cancer Drugs market, by product, 2015 - 2026 (USD Million)
-
Table U.S. Urological Cancer Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Canada Urological Cancer Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Canada Urological Cancer Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Canada Urological Cancer Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Europe Urological Cancer Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Europe Urological Cancer Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Europe Urological Cancer Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Europe Urological Cancer Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.K. Urological Cancer Drugs market, by type, 2015 - 2026 (USD Million)
-
Table U.K. Urological Cancer Drugs market, by product, 2015 - 2026 (USD Million)
-
Table U.K. Urological Cancer Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Germany Urological Cancer Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Germany Urological Cancer Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Germany Urological Cancer Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table France Urological Cancer Drugs market, by type, 2015 - 2026 (USD Million)
-
Table France Urological Cancer Drugs market, by product, 2015 - 2026 (USD Million)
-
Table France Urological Cancer Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Italy Urological Cancer Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Italy Urological Cancer Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Italy Urological Cancer Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Spain Urological Cancer Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Spain Urological Cancer Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Spain Urological Cancer Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Asia Pacific Urological Cancer Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Asia Pacific Urological Cancer Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Asia Pacific Urological Cancer Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Asia Pacific Urological Cancer Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table China Urological Cancer Drugs market, by type, 2015 - 2026 (USD Million)
-
Table China Urological Cancer Drugs market, by product, 2015 - 2026 (USD Million)
-
Table China Urological Cancer Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Japan Urological Cancer Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Japan Urological Cancer Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Japan Urological Cancer Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table India Urological Cancer Drugs market, by type, 2015 - 2026 (USD Million)
-
Table India Urological Cancer Drugs market, by product, 2015 - 2026 (USD Million)
-
Table India Urological Cancer Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Latin America Urological Cancer Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Latin America Urological Cancer Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Latin America Urological Cancer Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Latin America Urological Cancer Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Brazil Urological Cancer Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Brazil Urological Cancer Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Brazil Urological Cancer Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Mexico Urological Cancer Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Mexico Urological Cancer Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Mexico Urological Cancer Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Argentina Urological Cancer Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Argentina Urological Cancer Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Argentina Urological Cancer Drugs market, by application, 2015 - 2026 (USD Million)
-
Table MEA Urological Cancer Drugs market, by country, 2015 - 2026 (USD Million)
-
Table MEA Urological Cancer Drugs market, by type, 2015 - 2026 (USD Million)
-
Table MEA Urological Cancer Drugs market, by product, 2015 - 2026 (USD Million)
-
Table MEA Urological Cancer Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table South Africa Urological Cancer Drugs market, by type, 2015 - 2026 (USD Million)
-
Table South Africa Urological Cancer Drugs market, by product, 2015 - 2026 (USD Million)
-
Table South Africa Urological Cancer Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Nigeria Urological Cancer Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Nigeria Urological Cancer Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Nigeria Urological Cancer Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Company market position analysis
Table Company Profiles
Table Abbott Laboratories Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Novartis Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Sanofi SA Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bristol-Myers Squibb Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Astellas Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Sanofi S.A. Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table AstraZeneca Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Ipsen Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Johnson & Johnson Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Indevus Pharmaceuticals Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Pfizer Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Celgene Corporation Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table GlaxoSmithKline Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Ferring Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Dendreon Corporation Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Roche Healthcare Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
-
